14 April 2026
Oxford BioTherapeutics enters strategic collaboration with Bristol Myers Squibb to discover and develop next-generation T-cell engagers for solid tumours
• Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets … • This is OBT’s third major pharma collaboration within the past 12 months and reflects...
13 April 2026
European Medicines Agency adopts positive opinion for Bopediat® (furosemide) as Proveca’s third Paediatric Use Marketing Authorisation
This press release is intended for investors only … Proveca Ltd. is delighted to announce that on the 26th of March 2026, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a...
25 March 2026
Proveca submits a New Drug Application to the U.S. Food and Drug Administration
This press release is intended for investors only … Proveca Ltd submits a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Aqumeldi® (enalapril maleate), a prescription drug. The submission is made for the following indications: • Treatment of...
23 March 2026
Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea
Press release intended for investors only … 20 March 2026 – Proveca and BCWorld Healthcare (hereinafter BCW) are pleased to announce the launch of Sialanar® (glycopyrronium) in South Korea today. Sialanar® is the first licensed product approved in South Korea for the symptomatic...
10 March 2026
Monument Therapeutics announces first patient dosed in clinical trial of MT1988 in patients at clinical high risk for psychosis
Manchester, UK, March 10, 2026 - Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis. The study is being conducted...
23 February 2026
Biofortuna pioneers new robotic system for diagnostic tests
A North Wales biotechnology company has developed a new robotic dispensing system designed to improve the production of diagnostic testing devices used to detect conditions including cancer. Deeside-based Biofortuna secured £225,000 through the Welsh Government’s SMART Flexible...
11 February 2026
Proveca announces exclusive worldwide development and license agreement with Catalent for its Zydis® ODT technology for use with Glycopyrrolate
This press release is intended for investors only. 10th February 2026 - Proveca, a pharmaceutical company specialising in medicines for children, announced today that it has entered into an exclusive worldwide development and license agreement with Catalent, a leading global...
21 January 2026
QV Bioelectronics receives £4.5m boost for implantable brain cancer therapy
A Cheshire-based medtech business has secured £4.5m of investment and grant funding to revolutionise treatment for the most common type of primary brain cancer in adults. The investment round was led by PXN Ventures, which launched following the merger between Praetura Ventures...
10 December 2025
Oxford BioTherapeutics enters into strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer
• Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets … • The agreement - OBT's second high-profile pharma collaboration this year - reflects the strong validation of...
9 December 2025
Welsh Government Ministers visit Biofortuna to celebrate innovation and skills development
Biofortuna, a leading diagnostics manufacturer and laboratory services provider, welcomed Welsh Government Ministers Ken Skates MS and Jack Sargeant MS on Monday (8th December) to demonstrate how the Deeside-based CDMO is playing a pivotal role in the early detection of disease.